|
|
|
|
|
|
|
05.06.26 - 15:01
|
Photocure ASA - Notice of the Annual General Meeting 26 June 2026 (Cision)
|
|
|
Oslo, Norway, 5 June 2026: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 26 June 2026 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal").
The general meeting will be webcasted live and a link will be available on the company's website in due time in advance of the general meeting. It will not be possible to attend in person. Shareholders may also vote in advance or submit a proxy with voting instructions.
The notice convening the general meeting,...
|
|
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 14:03
|
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions (GlobeNewswire EN)
|
|
|
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026 Scientific Sessions, taking place on June 11 – 14, 2026 in Chicago, Illinois....
|
|
|
|
|
|
|
|
|
|
|
|
|
02.06.26 - 09:51
|
QIAGEN Buy (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass Qiagens Tuberkulose-Bluttest Quantiferon nach wie ......
|
|
|
02.06.26 - 08:33
|
Nanobiotix Joins the Euronext Tech Leaders Index (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors....
|
|
|
|
|
|
|
01.06.26 - 14:03
|
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses....
|
|
|
01.06.26 - 07:03
|
IBA launches Cyclone® iKure, a cyclotron designed for industrial scale Astatine-211 production (GlobeNewswire EN)
|
|
|
Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
